From the last CCFurthermore, the funding for dosing of the 16 Phase 1 patients is firmly embedded in our '23 and '24 budgets. We're now accelerating outreach to potential partners for the additional phases of development of Sudocetaxel Zendusortide, as well as capitalizing on the full potential of our SORT1 technology as a game-changer in anticancer therapy.